Chimerix, Inc. Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection
4/24/2013 11:41:33 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DURHAM, N.C., April 24, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the final study design for the Phase 3 SUPPRESS trial of CMX001 in the prevention of cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT). CMX001 is an investigational oral nucleotide analog lipid-conjugate that has shown broad-spectrum antiviral activity against double-stranded DNA (dsDNA) viruses including all of the herpesviruses, adenoviruses and polyomaviruses.
Help employers find you! Check out all the jobs and post your resume.
comments powered by